Biotech Investment Analyst — Drug Asset & Company Assessment

$120–200/hrrate as listed

Mercor is running a short paid pilot in which biotech investment analysts build and critique rubrics for evaluating commercial drugs and clinical-stage development programs. You will assess roughly 5–10 companies end-to-end — mechanism, clinical data, competitive position, value drivers — and judge whether an investment-style thesis holds up under scrutiny.

Summary, eligibility guidance and screening preparation are prepared by Sidequest from the platform's posting. Check the source listing before applying.

What the work involves

The research team behind this pilot wants to know whether AI-generated analysis of drug assets survives contact with someone who has underwritten these names professionally. Your output is two-sided: you write and refine the rubrics that define what a good asset assessment looks like, and you apply those rubrics to a working set of about 5–10 companies. Expect to move between mechanism-of-action plausibility, trial design and readout quality, competitive and regulatory positioning, and the commercial assumptions that carry a valuation.

A large share of the time goes to thesis critique. You will read investment-style write-ups and mark where the reasoning is thin: an efficacy delta treated as durable on a single Phase 2, a peak-sales estimate that ignores an entrenched standard of care, a safety signal waved through, an approval timeline that assumes a clean panel. Written justification matters more than the verdict — the team is training on your reasoning, not your score.

What the platform screens for

Specialist-fund background. Mercor's screen probes where you sat, what you covered, and what you actually underwrote. Generalist healthcare coverage or broad life-sciences consulting typically does not clear this bar.
Depth under follow-up. Expect the interview to pick one therapeutic area you name and keep going: endpoints, comparators, the specific readout that moved your view.
Calibration. Screens favor analysts who separate what the data supports from what the narrative implies, and who can say where they were wrong before.
Written clarity. Rubric work is writing work; terse, defensible prose beats volume.

Logistics

Remote and US-based, asynchronous, roughly 10–20 hours across a 1–2 week window. Pay in this category has been observed in the $120–200/hr range depending on background and pilot scope — treat that as observed, not guaranteed. Strong contributors are typically invited back as the program scales, but the initial commitment is the pilot only.

What they look for

5+ years evaluating biotech/pharma companies or assets at a specialist fund
End-to-end drug asset assessment: mechanism, clinical data, competitive position, value drivers
Critical reading of clinical trial design, endpoints, and readouts
Investment thesis construction and critique, including assumption stress-testing
Clear written justification of scores and rubric design
US-based, able to work asynchronously within a 1–2 week window

Before you apply

Would you pass this screen?

Drawn from what this listing actually requires. Answered in your browser — nothing is sent to us, and we do not store your answers.

Are you currently based in the United States?
US-based location · required
Have you worked as an analyst or investor at a specialist biotech or healthcare investment fund (not generalist, hedge fund, or trading)?
Specialist-fund biotech/pharma background · required
Do you have 5 or more years of professional experience evaluating biotech or pharmaceutical companies or drug assets?
5+ years biotech/pharma evaluation · required
Are you familiar with the clinical and regulatory pathway for biotech/pharma drug development (preclinical through FDA approval)?
Familiarity with drug-development programs · preferred

0 of 4 answered

Included with this listing

Interview prep — 11 questions

Matched to what this platform's screening actually measures. Answer each out loud in 60–90 seconds: claim → concrete example → implication.

What it tests: Whether the candidate can articulate a real, multi-factor investment decision with specific clinical/commercial evidence, not armchair speculation. Tests depth of deal experience and ability to synthesize disparate data.
A strong answer: Names a concrete company or late-stage asset, identifies 2–3 key value drivers (e.g., clinical efficacy data, competitive position, market size), and explains why each mattered to the investment case. Shows familiarity with both the science and the commercial reality.
Where people lose it: Speaks in generalities ('biotech has high risk, needs good data') without a specific deal, or fixates on a single metric (stock price, market cap) while ignoring the mechanism or clinical rationale.